Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the phoenix criteria for biochemical recurrence after curative radiotherapy
Analysis of AR-FL and AR-V1 in whole blood of patients with castration resistant prostate cancer as a tool for predicting response to abiraterone acetate
Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study
Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy